Source Count: 14 | Weighted Score: 33 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: April 10, 2026
Keywords: psychedelic, psilocybin, DMT, dimethyltryptamine, LSD, 5-HT2A receptor, serotonin, default mode network, entropy, mystical experience, neuroimaging, claustrum, thalamic gating, REBUS model, psychedelic therapy, neuroplasticity, ego dissolution
Category Tags: psychedelic-neuroscience, psilocybin, dmt, serotonin-receptor, default-mode-network, consciousness-research
Cross-References: K_3_01 — Consciousness Variants Overview · Y_1_01 — Psychedelics Pharmacology Overview · K_2_01 — Neuroscience Brain Overview

QUICK SUMMARY

The psychedelic renaissance in neuroscience — a period of renewed scientific investigation beginning circa 2006 after decades of regulatory restriction — has produced an unprecedented body of neuroimaging, pharmacological, and clinical data revealing how classical psychedelics (psilocybin, LSD, DMT, mescaline) alter consciousness at the neural level. KEY FINDING All classical psychedelics are partial agonists at the serotonin 5-HT2A receptor, a G-protein coupled receptor (Gq/11 signaling) concentrated in cortical layer V pyramidal neurons — the demonstration that 5-HT2A activation is necessary and sufficient for the psychedelic experience was established through ketanserin (a selective 5-HT2A antagonist) blocking experiments: Franz Vollenweider et al. at the University of Zurich (1998, Neuropsychopharmacology) showed that pre-treatment with ketanserin completely blocked psilocybin's subjective effects, and this finding has been replicated for LSD (Preller et al., 2017, Current Biology) and DMT. KEY FINDING The default mode network (DMN) — a set of brain regions (medial prefrontal cortex, posterior cingulate cortex, angular gyrus, hippocampal formation) active during self-referential thought and mind-wandering — shows characteristic desynchronization and reduced functional connectivity under psychedelics. Robin Carhart-Harris at Imperial College London published the first fMRI study of psilocybin (2012, Proceedings of the National Academy of Sciences), finding that psilocybin decreased blood flow and BOLD signal in the DMN — particularly the medial prefrontal cortex (by ~20%) and posterior cingulate cortex (by ~16%) — contradicting the prior assumption that psychedelics increase brain activity globally. The magnitude of DMN desynchronization correlated with subjective reports of ego dissolution (the loss of the sense of a bounded self), suggesting that the DMN's integrative activity underlies the construction of the ego in ordinary consciousness. KEY FINDING Carhart-Harris and Karl Friston formalized these observations in the REBUS (Relaxed Beliefs Under Psychedelics) and Anarchic Brain model (2019, Pharmacological Reviews), which applies Friston's free energy principle to psychedelic states: psychedelics relax the precision weighting of high-level prior beliefs (encoded in the DMN and other association cortices), allowing bottom-up sensory information to exert greater influence on perception and cognition — this produces the characteristic phenomenology of enhanced pattern perception, synesthesia, emotional lability, and mystical-type experience. The entropy of brain signal activity increases under psychedelics (Schartner et al., 2017, Scientific Reports), consistent with the REBUS framework. N,N-Dimethyltryptamine (DMT) — the active component of ayahuasca and an endogenous trace amine in the mammalian brain (detected in rat brain by Steven Barker et al., 2012, and in living human cerebrospinal fluid) — has emerged as a key molecule for consciousness research. Christopher Timmermann et al. at Imperial College (2019, Scientific Reports) recorded EEG during intravenous DMT administration and found that DMT shifts brain dynamics toward a state characterized by increased alpha band power decrease, theta band power increase, and emergence of novel broadband oscillatory signatures distinct from known sleep or waking states — the phenomenology (vivid entity encounters, spatial distortions, perception of "other dimensions") occurs within a remarkably brief window of ~10–20 minutes for IV-DMT. Psilocybin (4-phosphoryloxy-DMT, prodrug dephosphorylated to psilocin in the body) has become the most clinically studied psychedelic: Roland Griffiths at Johns Hopkins University published the landmark trial (2006, Psychopharmacology) showing that a single high-dose session (30 mg/70 kg) in a supportive setting produced mystical-type experiences rated by 67% of volunteers as among the "top five most meaningful experiences of their lives" at 14-month follow-up — this finding has been replicated across multiple institutions and cultures.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 5-HT2A Receptor Is the Primary Target

• Vollenweider et al. (1998) established that ketanserin (5-HT2A antagonist) completely blocks psilocybin's subjective effects in humans — replicated for LSD (Preller et al., 2017), confirming that 5-HT2A activation is the necessary pharmacological mechanism for classical psychedelic effects

1.2 DMN Desynchronization Under Psilocybin

• Carhart-Harris et al. (2012, PNAS) demonstrated reduced BOLD signal and functional connectivity in the DMN during psilocybin — the magnitude of DMN disruption correlated with intensity of ego dissolution, a finding replicated by Muthukumaraswamy et al. (2013, MEG data) and across LSD and ayahuasca studies

1.3 Psilocybin Produces Enduring Positive Effects

• Griffiths et al. (2006, 2008, 2011) at Johns Hopkins showed that single high-dose psilocybin sessions produced sustained increases in well-being, life satisfaction, and prosocial attitudes at 14-month and ~30-month follow-ups — the study used a double-blind crossover design with methylphenidate as active control

1.4 Increased Neural Entropy Under Psychedelics

• Schartner et al. (2017, Scientific Reports) used Lempel-Ziv complexity analysis on MEG data from subjects under psilocybin, LSD, and ketamine — all three psychedelics increased neural signal diversity above the waking baseline, providing the first quantitative evidence that psychedelic states represent a higher-entropy form of consciousness

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 REBUS Model

• Carhart-Harris and Friston (2019) proposed that psychedelics relax the precision weighting of high-level predictive models (priors), increasing the influence of bottom-up prediction errors — this integrates multiple observed phenomena (ego dissolution, enhanced sensory experience, emotional release) under Friston's free energy framework; while increasingly accepted, the model's predictions regarding specific computational parameters have not been fully tested

2.2 Psilocybin for Treatment-Resistant Depression

• Carhart-Harris et al. (2016, The Lancet Psychiatry) published an open-label trial of psilocybin for treatment-resistant depression showing rapid and sustained symptom reduction in 12 patients at 3-month follow-up — the COMPASS Pathways Phase IIb trial (2022, New England Journal of Medicine, n=233) confirmed efficacy of the 25 mg dose versus 1 mg control, though remission rates (29.1% vs. 7.6%) indicated psilocybin is not universally effective

2.3 Neuroplasticity Enhancement

• Ly et al. (2018, Cell Reports) demonstrated that DMT, LSD, and psilocin promote dendritic growth and spinogenesis in cortical neurons (rat model), likely through TrkB (BDNF receptor) and mTOR signaling pathways — this suggests psychedelics may produce lasting therapeutic effects through structural neural remodeling, not just acute pharmacological action

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Endogenous DMT Release During Near-Death Experiences

• DMT is present in mammalian brain tissue (Barker et al., 2012; Dean et al., 2019, confirmed DMT synthesis in living rat cortex via immunohistochemistry) — the hypothesis that endogenous DMT release mediates near-death experiences (proposed by Rick Strassman, DMT: The Spirit Molecule, 2001) is pharmacologically plausible but unproven, as no study has measured DMT levels during cardiac arrest or near-death states in humans

3.2 Psychedelic Entity Encounters as Contact with External Intelligence

• Reports of encounters with seemingly autonomous "entities" during DMT experiences are consistent across cultures and dosing conditions (Strassman's 1990–1995 DEA-approved DMT study at UNM; Michael Winkelman, 2018) — whether these represent genuine contact with external intelligence, archetypally structured hallucinations, or artifacts of neural network dynamics remains unanswerable by current methodology

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Psychedelics Cause Permanent Brain Damage

• DEBUNKED Population studies by Johansen and Krebs (2015, Journal of Psychopharmacology) analyzing ~130,000 respondents from the U.S. National Survey on Drug Use and Health found no association between lifetime psychedelic use and increased rates of mental health problems, suicidality, or psychological distress — psychedelics have no documented neurotoxicity at standard doses

4.2 LSD Causes Chromosome Damage

• DEBUNKED The claim — originating from a 1967 Science paper by Maimon Cohen et al. reporting LSD-induced chromosome breakage in cultured leukocytes — was contradicted by subsequent studies: Dishotsky et al. (1971, Science) reviewed 68 studies and concluded that LSD at standard doses does not cause chromosomal damage, birth defects, or genetic mutations in humans

Counter-Arguments & Criticisms

Expectation and Set-and-Setting Confounds

• Psychedelic trials are difficult to blind (participants typically know whether they received an active dose) — Muthukumaraswamy et al. (2021) argued that expectation effects may inflate therapeutic outcomes; the use of active placebos (low-dose psychedelic or niacin) only partially addresses this

Clinical Scalability

• Psychedelic-assisted therapy requires 6–8 hours of therapist time per dosing session — Matthew Johnson at Johns Hopkins has noted that the cost and time requirements create barriers to large-scale clinical implementation, distinguishing psychedelics from conventional daily-use medications

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Carhart-Harris, Robin L., et al | 2012 | "Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin" | Proceedings of the National Academy of Sciences | ∅ | 109.6::2138–2143 | ∅ | ∅ | doi:10.1073/pnas.1119598109 | ∅ | ∅ | ∅
2. Carhart-Harris, Robin L.; Karl J | 2019 | "REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics" | Pharmacological Reviews | ∅ | 71.3::316–344 | Friston | ∅ | doi:10.1124/pr.118.017160 | ∅ | ∅ | ∅
3. Griffiths, Roland R., et al | 2006 | "Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance" | Psychopharmacology | ∅ | 187::268–283 | ∅ | ∅ | doi:10.1007/s00213-006-0457-5 | ∅ | ∅ | ∅
4. Vollenweider, Franz X., et al | 1998 | "Psilocybin Induces Schizophrenia-Like Psychosis in Humans via a Serotonin-2 Agonist Action" | Neuroreport | ∅ | 9.17::3897–3902 | ∅ | ∅ | doi:10.1097/00001756-199812010-00024 | ∅ | ∅ | ∅
5. Timmermann, Christopher, et al | 2019 | "Neural Correlates of the DMT Experience Assessed with Multivariate EEG" | Scientific Reports | ∅ | 9.1::16324 | ∅ | ∅ | doi:10.1038/s41598-019-51974-4 | ∅ | ∅ | ∅
6. Schartner, Michael M., et al | 2017 | "Increased Spontaneous MEG Signal Diversity for Psychoactive Doses of Ketamine, LSD and Psilocybin" | Scientific Reports | ∅ | 7::46421 | ∅ | ∅ | doi:10.1038/srep46421 | ∅ | ∅ | ∅
7. Ly, Calvin, et al | 2018 | "Psychedelics Promote Structural and Functional Neural Plasticity" | Cell Reports | ∅ | 23.11::3170–3182 | ∅ | ∅ | doi:10.1016/j.celrep.2018.05.022 | ∅ | ∅ | ∅
8. Strassman, Rick | 2001 | ∅ | DMT: The Spirit Molecule | ∅ | ∅ | Rochester: Park Street Press | ∅ | isbn:9780892819270 | ∅ | ∅ | ∅
9. Preller, Katrin H., et al | 2017 | "The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation" | Current Biology | ∅ | 27.3::451–457 | ∅ | ∅ | doi:10.1016/j.cub.2016.12.030 | ∅ | ∅ | ∅
10. Johansen, Pål-Ørjan; Teri Suzanne Krebs | 2015 | "Psychedelics Not Linked to Mental Health Problems or Suicidal Behavior" | Journal of Psychopharmacology | ∅ | 29.3::270–279 | ∅ | ∅ | doi:10.1177/0269881114568039 | ∅ | ∅ | ∅
11. Carhart-Harris, Robin L., et al. | 2016 | "Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study" | The Lancet Psychiatry | ∅ | 3.7::619–627 | ∅ | ∅ | doi:10.1016/S2215-0366(16)30065-7 | ∅ | ∅ | ∅
12. Dean, Jon G., et al | 2019 | "Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain" | Scientific Reports | ∅ | 9::9333 | ∅ | ∅ | doi:10.1038/s41598-019-45812-w | ∅ | ∅ | ∅
13. Dishotsky, Norman I., et al | 1971 | "LSD and Genetic Damage" | Science | ∅ | 172.3982::431–440 | ∅ | ∅ | doi:10.1126/science.172.3982.431 | ∅ | ∅ | ∅
14. Goodwin, Guy M., et al | 2022 | "Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression" | New England Journal of Medicine | ∅ | 387.18::1637–1648 | ∅ | ∅ | doi:10.1056/NEJMoa2206443 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 10, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/S2215-0366(16)30065-7. Corpus hygiene campaign, Phase 4, 2026-07-29.